Evinacumab in Patients with Refractory Hypercholesterolemia
Robert S. Rosenson(Mount Sinai Hospital), Daniel Gaudet(Brigham and Women's Hospital), Vladimir Son(Innsbruck Medical University), Robert Pordy(Inserm), Robert L. Hamlin(The Ohio State University), Shazia Ali(Regeneron (United States)), Nagwa Khilla(Regeneron (United States)), Christoph Ebenbichler(Innsbruck Medical University), Seth J. Baum(Boca Raton Regional Hospital), Erik S.G. Stroes(Amsterdam University Medical Centers), Yuping Dong(Innsbruck Medical University), Lesley Burgess(Stellenbosch University)
Cited by 294
Related Papers
Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
|New England Journal of Medicine|2018|3.5k
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society
|European Heart Journal|2013|2.7k
The common PPARγ Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes
|Nature Genetics|2000|1.8k
Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management
|European Heart Journal|2015|1.4k
Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement
|European Heart Journal|2022|1.3k